You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes

Citation Tools

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Jaderberg M, Cedres S, Paz-Ares L, et al
361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0361